Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John T Hunt

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Bioorganic & Medicinal Chemistry Letters|August 23, 2005
New dual inhibitors of EGFR and HER2 protein tyrosine kinasesBrian E Fink, Gregory D Vite, Harold Mastalerz, et al.
Cancer Research|June 3, 2004
Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor modelsVeeraswamy Manne, Francis Y F Lee, David K Bol, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2018
Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-formMicah T Nelp, Patrick A Kates, John T Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonistsAaron Balog, Mark E Salvati, Weifang Shan, et al.
Molecular Cancer Therapeutics|January 28, 2010
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinasesRajeev S Bhide, Louis J Lombardo, John T Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2013
Design, synthesis, functional and structural characterization of an inhibitor of N-acetylneuraminate-9-phosphate phosphatase: observation of extensive dynamics in an enzyme/inhibitor complexSoong-Hoon Kim, Keith L Constantine, Gerald J Duke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase familiesTai W Wong, Francis Y Lee, Stuart Emanuel, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 2018
Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitorsDavid K Williams, Jay A Markwalder, Aaron J Balog, et al.
Journal of Medicinal Chemistry|June 10, 2005
Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitorsRobert M Borzilleri, Xiaoping Zheng, Ligang Qian, et al.
Journal of Medicinal Chemistry|June 23, 2006
Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2Robert M Borzilleri, Rajeev S Bhide, Joel C Barrish, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|August 23, 2005
New dual inhibitors of EGFR and HER2 protein tyrosine kinasesBrian E Fink, Gregory D Vite, Harold Mastalerz, et al.
Cancer Research|June 3, 2004
Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor modelsVeeraswamy Manne, Francis Y F Lee, David K Bol, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2018
Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-formMicah T Nelp, Patrick A Kates, John T Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|November 18, 2004
The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonistsAaron Balog, Mark E Salvati, Weifang Shan, et al.
Molecular Cancer Therapeutics|January 28, 2010
The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinasesRajeev S Bhide, Louis J Lombardo, John T Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|June 11, 2013
Design, synthesis, functional and structural characterization of an inhibitor of N-acetylneuraminate-9-phosphate phosphatase: observation of extensive dynamics in an enzyme/inhibitor complexSoong-Hoon Kim, Keith L Constantine, Gerald J Duke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase familiesTai W Wong, Francis Y Lee, Stuart Emanuel, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 2018
Development of a series of novel o-phenylenediamine-based indoleamine 2,3-dioxygenase 1 (IDO1) inhibitorsDavid K Williams, Jay A Markwalder, Aaron J Balog, et al.
Journal of Medicinal Chemistry|June 10, 2005
Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitorsRobert M Borzilleri, Xiaoping Zheng, Ligang Qian, et al.
Journal of Medicinal Chemistry|June 23, 2006
Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2Robert M Borzilleri, Rajeev S Bhide, Joel C Barrish, et al.
Pageof 4